A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients

Authors: Hegg, Roberto ^*, Mattar, André, de Matos, João Nunes, Neto, Pedrini, José Luiz, Aleixo, Sabina Bandeira, Rocha, Roberto Odebrecht, Cramer, Renato Peixoto, Junior, van-Eyll-Rocha, Sylvie

Source: In Clinics 2016 71(10):586-592